Skip to main content
Gene exon skipping therapy delivered for duchenne muscular dystrophy for the first time in India

Duchenne Muscular Dystrophy (DMD) is a genetic disorder affecting mostly the male children who suffer from muscle wasting and they typically live only until 35 years of age. Until 2019 there was no definitive treatment of DMD but in 2019 FDA approved a Genetic Engineered Medicine called Vyondys 53 for its treatment. A total of 26 children have been given this medicine since then and have shown promising results. Vyondys 53 is a Gene codon correction at the defective DNA level.

In India Kenmax Multispeciality Hospital, Madurai has become the first in the country to receive the ‘Gene exon Skipping therapy’ which has been delivered to a 10 year old patient suffering from DMD under the guidance of Dr. K. Raghavan, a renowned paediatric Neurologist. The patient was diagnosed with DMD at the age of 3.5 years. This young patient is the 27th patient in the world to receive this advanced treatment. JOGO Health which provides the patient neuro-muscular assessment and then the digital neuro-rehab therapy has been roped in to evaluate and help in the functional recovery of the child. As opined by specialists Vyondys 53 is by far the most advanced and definitive treatment of DMD. As per the neuro-therapists from JOGO Health, the patient has shown very good progress since the administration of Gene Therapy alongwith the digital therapeutics from JOGO.

Kenmax multi-speciality hospital is 50 bedded, located in the heart of Madurai which specially  focusus on people with rare Genetic neurological disorders like Muscular Dystrophy, Neuro-Rehabilitation, Behavioural disorders in children and Special Education needs. Kenmax Multispeciality hospital has now tied up with JOGO Health to take care of such patients collaboratively. Kenmax is one of the Government of India Clinical Trials Registry of India (CTRI) registered institutions for clinical research and are presently involved in Gut-Brain Axis study in collaboration and funded by University of Okinawa, Japan. This study is an approved CTRI study. Current work is also going on the influence of Yoga on Neurotransmitters in Autism.

SOURCE: www.techplusmedia.com

InnoHEALTH magazine digital team

Author InnoHEALTH magazine digital team

More posts by InnoHEALTH magazine digital team

Leave a Reply

%d bloggers like this: